Pharmaceutical Cannabis - Estonia

Estonia

Estonia is expected to witness a significant growth in revenue within the Pharmaceutical Cannabis sector, with projections indicating a figure of US$1.04m in 2024.
This growth is anticipated to continue, with an estimated annual growth rate (CAGR 2024-2029) of 4.88%, leading to a market volume of US$1.32m by 2029.
When compared on a global scale, the United States is poised to generate the highest revenue, amounting to US$913.10m in 2024.
In terms of per capita analysis, in 2024, each individual in Estonia is expected to contribute revenues of US$3.76k.
Estonia's pharmaceutical cannabis market shows promising growth potential with increasing research and development activities for medicinal applications.

Key regions: United States, Spain, Europe, Thailand, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceutical Cannabis market in Estonia is experiencing a surge in demand and development, mirroring the global trend towards the acceptance and legalization of medical cannabis.

Customer preferences: In Estonia, customers are increasingly seeking alternative and natural remedies for various health conditions, driving the demand for pharmaceutical cannabis products. Patients are showing a growing interest in the potential therapeutic benefits of cannabis-based medications, leading to a shift in consumer preferences towards these products.

Trends in the market: One of the notable trends in the Pharmaceutical Cannabis market in Estonia is the expanding availability of cannabis-based pharmaceuticals in pharmacies and healthcare facilities. This accessibility is contributing to the growing acceptance and integration of medical cannabis into the mainstream healthcare system. Additionally, there is a rising trend of research and development activities focused on creating innovative cannabis-derived medications tailored to specific medical needs in the country.

Local special circumstances: Estonia's unique position as a European Union (EU) member state influences the development of its Pharmaceutical Cannabis market. The country's adherence to EU regulations and standards ensures the quality and safety of cannabis-based pharmaceuticals available in the market. Furthermore, Estonia's progressive stance on healthcare and wellness issues creates a conducive environment for the growth of the Pharmaceutical Cannabis sector.

Underlying macroeconomic factors: The economic stability and growth in Estonia play a crucial role in the expansion of the Pharmaceutical Cannabis market. With a stable economy and increasing disposable income levels, consumers in Estonia have greater purchasing power to afford pharmaceutical cannabis products. Moreover, the government's initiatives to support research and innovation in the healthcare sector contribute to the overall development of the Pharmaceutical Cannabis market in the country.

Methodology

Data coverage:

Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.

Modeling approach / Market size:

Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.